Condition
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Transthyretin Amyloid Cardiomyopathy (ATTR-CM) clinical trials that are recruiting, at sites in 31 countries (most in Belgium (2), Denmark (2), France (2)). By phase: Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 31Countries
Newest Transthyretin Amyloid Cardiomyopathy (ATTR-CM) clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Acoramidis in adults with transthyretin amyloid cardiomyopathy in France | — | Many Locations | Recruiting | Aug 27, 2026 |
| Acoramidis for transthyretin amyloid cardiomyopathy in routine care | — | Multiple Locations and 16 other locations | Recruiting | Nov 19, 2025 |
| Coramitug (NNC6019-0001) for heart failure from transthyretin amyloid cardiomyopathy | Phase 3 | Phoenix, Arizona and 298 other locations | Recruiting | Oct 6, 2025 |
| Registry for studying Transthyretin Amyloid Cardiomyopathy in Thailand | — | Bangkok and 7 other locations | Recruiting | Apr 1, 2024 |
All recruiting trials (4)
-
Acoramidis in adults with transthyretin amyloid cardiomyopathy in France
This is an observational study to see how acoramidis is used in everyday care for adults with ATTR‑CM in France and how it affects their quality of life and daily function.
-
Acoramidis for transthyretin amyloid cardiomyopathy in routine care
See how acoramidis works for adults with transthyretin amyloid cardiomyopathy (wild-type or variant) when given as part of regular clinical care.
-
Coramitug (NNC6019-0001) for heart failure from transthyretin amyloid cardiomyopathy
This study tests whether coramitug (NNC6019-0001) can lower the risk of heart-related death and illness in adults with transthyretin amyloid cardiomyopathy (ATTR-CM) while they continue their usual heart medicines.
-
Registry for studying Transthyretin Amyloid Cardiomyopathy in Thailand
This study is collecting information from people with Transthyretin Amyloid Cardiomyopathy in Thailand to better understand the disease and improve early detection and treatment options.
Quick answers
How many Transthyretin Amyloid Cardiomyopathy (ATTR-CM) clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 31 countries. The most sites are in Belgium (2 trials), Denmark (2 trials), France (2 trials), Germany (2 trials), Italy (2 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.